EverLift Submucosal Lifting Agent in a 10mL Syringe Receives FDA Clearance

B2B Training: What’s the Most Effective Way of Learning?

B2B training, which is short for business-to-business training, is a popular and convenient type of training that enables entire companies to train their teams...

AlixPartners Forecasts: Household Products Could Cost U.S. Manufacturers and Consumers 15% More This Year Due to Resin Shortage

While companies can’t control the market forces at play, they can take action to mitigate the risk and impact of supply chain disruption.

October 23, 2020

EverLift Submucosal Lifting Agent in a 10mL syringe, a new device for the lift of polyps, adenomas, early-stage cancers, and other gastrointestinal lesions prior to excision with a snare or other appropriate endoscopic devices, has received FDA clearance. The news was announced today by GI Supply.

EverLift Submucosal Lifting Agent is the only pre-filled Submucosal Lifting Agent in the market available in two presentations, 5mL and 10mL, providing physicians the flexibility to use only what they need and potentially reducing costs to hospitals and ambulatory surgery centers. Also, the pre-filled syringe eliminates the time and expense associated with mixing and preparing the agent.

The new EverLift device provides margin delineation of the lesions with a darker blue color than that offered by other manufacturers1. The darker color is intended to enable safe and complete polyp resections.

“Lifting agents aid in safer resections for patients.  EverLift provides a pliable yet reliable cushion for resection and darker blue hues. The single serve dosing helps reduce waste for everyday polypectomies.” – Dr. Gary “Taavi” Reiss Assistant Professor of Clinical Medicine LSU Health and Director of Interventional GI Metropolitan Gastroenterology Associates.

EverLift’s formulation is cellulose-based, making it hypertonic. This results in a lifting agent that is specially formulated with water-retaining properties, which causes a slower rate of absorption because of osmotic resistance. With an absorption rate slower than other currently available agents2, EverLift provides gastroenterologists with a long lift during their resection procedures.

“The launch of EverLift 10mL completes our offering as now we have two separate presentations of lifting agents in a 5mL and 10mL syringe, to give physicians more flexibility. We are committed to continuing to invest in innovation and this launch is another proof of our continuous investments,” said GI Supply CFO and Interim CEO Kristi Dahlke.

More here.


  1. Survey conducted at DDW, 2019
  2. Based on ex-vivo bench top studies and not in clinical use.
spot_img

DON'T MISS

Mediclinic Appoints 2 New Independent Non-Executive Directors

Natalia Barsegiyan and Zarina Bassa will bring significant and diverse skills and experience, complementing those of existing Board members. I am confident they will both be great additions to our Board of Directors.”

Asensus Surgical Appoints Two New Board Members

Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today announced the expansion of its Board of Directors, appointing...

Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.